---
title: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
date: '2024-07-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38959480/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240704182123&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In patients with recurrent cervical cancer, second- or
  third-line treatment with tisotumab vedotin resulted in significantly greater efficacy
  than chemotherapy. (Funded by Genmab and Seagen [acquired by Pfizer]; innovaTV 301
  ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with recurrent cervical cancer, second- or third-line treatment with tisotumab vedotin resulted in significantly greater efficacy than chemotherapy. (Funded by Genmab and Seagen [acquired by Pfizer]; innovaTV 301 ClinicalTrials.gov number, ...